drugset / Trial / NCT07222748

A Study of TLC590 for Postsurgical Pain Following Bunionectomy

NCT07222748

Phase 3 Active not recruiting 304 enrolled TLC Biopharmaceuticals, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a Phase 3, randomized, double-blind, comparator- and placebo-controlled study to evaluate analgesic efficacy and safety of TLC590 via local infiltration in adult subjects following bunionectomy.

Timeline

Start
2025-11-17
Primary completion
2026-06-12
Completion
2026-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified
Subject TLC590 Unknown Other

Indications

No indication recorded.